推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 爾康制藥(300267.SZ)公司人士表示，鑒于公司戰(zhàn)略規(guī)劃以及子公司間業(yè)務(wù)的協(xié)調(diào)，公司全資子公司湖南湘易康制藥此前擬計(jì)劃使用自有資金5320萬(wàn)元投資建設(shè)藥用明膠項(xiàng)目已經(jīng)終止。另一投資項(xiàng)目--藥用無(wú)水乙醇和藥用乙醇項(xiàng)目在今年3月時(shí)仍處建設(shè)期，截至目前證券部暫未收到新進(jìn)展通知。
2014年7月，爾康制藥發(fā)布公告稱，為進(jìn)一步完善和豐富公司產(chǎn)品結(jié)構(gòu)，公司全資子公司湖南湘易康制藥擬計(jì)劃使用自有資金3470萬(wàn)元投資建設(shè)藥用無(wú)水乙醇和藥用乙醇項(xiàng)目；使用自有資金5320萬(wàn)元投資建設(shè)藥用明膠項(xiàng)目。
公告顯示，藥用明膠的主要用途為制作軟硬膠囊外殼和藥片包衣，也可作為穩(wěn)定劑用于生物制品中，如病毒疫苗。項(xiàng)目建成后，將年產(chǎn)3500噸藥用明膠的生產(chǎn)線，建設(shè)周期預(yù)計(jì)為18個(gè)月，現(xiàn)已終止。
藥用無(wú)水乙醇和藥用乙醇項(xiàng)目建成后，將年產(chǎn)1萬(wàn)噸藥用無(wú)水乙醇、年產(chǎn)1萬(wàn)噸藥用乙醇的生產(chǎn)線，建設(shè)周期約為6個(gè)月。項(xiàng)目全面達(dá)產(chǎn)后，預(yù)計(jì)可實(shí)現(xiàn)的年凈利潤(rùn)約1997.7萬(wàn)元。根據(jù)其預(yù)計(jì)建設(shè)周期計(jì)算，該項(xiàng)目目前進(jìn)展或慢于預(yù)期。
據(jù)了解，乙醇和無(wú)水乙醇是重要的基本化工原料，廣泛用于醫(yī)藥、涂料、衛(wèi)生用品等各個(gè)方面，在藥品生產(chǎn)中，無(wú)水乙醇用作藥物合成反應(yīng)的溶媒、制劑用溶劑；乙醇除了在合成反應(yīng)中的應(yīng)用、生產(chǎn)醫(yī)用酒精外，還被廣泛運(yùn)用于中藥浸提。
